PeptiDream Inc. (TSE: 4587)
Health Care · Biotechnology · JP
¥1,108.50
-0.49% today · -29.9% 1Y
PeptiDream Inc. (TSE: 4587) operates in the Biotechnology industry within the Health Care sector. The company is valued at $894.25M and employs 745 people.
Over the last twelve months the share price has lost 29.9%, trading between 906.40 and 1.82K.
Tweenvest scores PeptiDream Inc. across four factors: quality 69/100, value 83/100. Its strongest factor is value.
4587 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $894.25M
- Revenue (TTM)
- $118.15M
- P/E
- —
- EPS
- -28.10
- Dividend yield
- —
- Beta (5Y)
- 0.16
- 52-week high
- ¥1,818.50
- 52-week low
- ¥906.40
- Avg volume (3M)
- —
- Shares outstanding
- 128.57M
- Employees
- 745
- Next earnings
- —
About PeptiDream Inc.
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.
- ISIN
- JP3836750004
- Founded
- 2006
- Listed since
- Jun 12, 2013
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.